The following table reconciles Net loss from continuing operations attributable to NantHealth to Net loss from continuing operations attributable to NantHealth- Non-GAAP for the years ended December 31, 2021 and 2020: (Dollars in thousands, except per share amounts) Year Ended December 31, 2021 2020 Net loss from continuing operations attributable to NantHealth $ (58,282) $ (88,319) Adjustments to GAAP net loss from continuing operations attributable to NantHealth: Loss from related party equity method investment — 31,702 Stock-based compensation expense from continuing operations 3,879 2,722 Loss on Exchange and Prepayment of 2016 Notes 742 — Change in fair value of derivatives liability (4) 4 Change in fair value of Bookings Commitment 2,323 11,168 Noncash interest expense related to convertible notes 622 6,477 Intangible amortization from continuing operations 8,880 8,395 Impairment of intangible assets, including internal-use software — 729 Securities litigation costs — (103) Tax provision (benefit) resulting from certain noncash tax items (60) 228 Total adjustments to GAAP net loss from continuing operations attributable to NantHealth 16,382 61,322 Net loss from continuing operations attributable to NantHealth - Non-GAAP $ (41,900) $ (26,997) Weighted average basic common shares outstanding 114,148,604 110,954,858 Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP $ (0.37) $ (0.24) The following table reconciles Net loss per common share from continuing operations attributable to NantHealth to Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Net loss per common share from continuing operations attributable to NantHealth $ (0.51) $ (0.80) Adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth: Loss from related party equity method investment — 0.29 Stock-based compensation expense from continuing operations 0.04 0.02 Loss on Exchange and Prepayment of 2016 Notes 0.01 — Change in fair value of derivatives liability — — Change in fair value of Bookings Commitment 0.01 0.10 Noncash interest expense related to convertible notes — 0.06 Intangible amortization from continuing operations 0.08 0.08 Impairment of intangible assets, including internal-use software — 0.01 Securities litigation costs — — Tax provision (benefit) resulting from certain noncash tax items — — Total adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth 0.14 0.56 Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP $ (0.37) $ (0.24) - 77 -
RkJQdWJsaXNoZXIy NTIzOTM0